Eli Lilly and Hong Kong-listed Metis TechBio announced a collaboration on October 19, 2026, to research tissue-specific drug-delivery technologies.
Metis will use its AI-driven AiLNP platform to discover and optimize ionizable lipids and lipid nanoparticles (LNPs), which can carry medicines such as RNA therapies. The goal is to help treatments reach selected tissues more effectively.
The headline value is conditional:
Metis is due a low-double-digit-million-dollar upfront payment and could receive up to about $1.1 billion in development, regulatory, and commercial milestones, plus tiered single-digit royalties on sales of any resulting products.
No specific drug candidate, disease target, or development timeline was disclosed. The $1.1 billion is a potential maximum, not guaranteed payment; it depends on programs reaching milestones.
Sources:
HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal ...
HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion
Lilly allies with Metis in $1.1B AI nanoparticle discovery deal
METiS TechBio, Eli Lilly Sign $1.1 Billion For AI-Designed ...
METiS signs $1.1B AI drug-delivery deal
Eli Lilly Teams Up with Hong Kong's Metis in $1.1 Billion Deal ...
Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech
Metis TechBio in Discovery Pact Potentially Worth More ...
Eli Lilly signs $1.1B drug-delivery pact with Metis TechBio
Eli Lilly Signs Up to $1.1 Billion Metis Deal
Metis TechBio Eli Lilly deal: up to $1.1B milestones
$1.1B China's First Large Generative AI-LNP Platform ...
Business News | China Labour Bulletin Board